Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250

富瑞集团维持渤健公司(BIIB.US)买入评级，维持目标价250美元

moomoo资讯 · 11/15 08:31 · 评级/大行评级

Jefferies analyst Michael Yee maintains $Biogen (BIIB.US)$ with a buy rating, and maintains the target price at $250.

According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of -1.0% over the past year.

AnalystRecentRatingAutoNews_206532_20241114_fff12de0a1e951ae96de7d40e39e7cd68516c49b_1731681066569068_mm_en

Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:

The strategy to counterbalance the diminishing core franchises involves focusing on developing treatments for conditions that are underserved and challenging to address. The pipeline is perceived to carry a higher clinical risk relative to its major biotech counterparts, which, in turn, presents considerable potential value.
Biogen's collaboration with Eisai on the MAA for lecanemab in amyloid-positive early Alzheimer's disease has seen progress, as the request for reexamination by the EMA's CHMP has resulted in a favorable recommendation, albeit excluding APOE4 homozygotes. This development is perceived as making the application more acceptable to the European Commission, which is anticipated to decide on the approval within a 67-day timeframe.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

富瑞集团分析师Michael Yee维持$渤健公司 (BIIB.US)$买入评级，维持目标价250美元。

根据TipRanks数据显示，该分析师近一年总胜率为41.5%，总平均回报率为-1.0%。

AnalystRecentRatingAutoNews_206532_20241114_fff12de0a1e951ae96de7d40e39e7cd68516c49b_1731681066569068_mm_sc

此外，综合报道，$渤健公司 (BIIB.US)$近期主要分析师观点如下：

平衡不断减少的核心特许经营权的策略包括专注于开发针对服务不足且难以解决的疾病的治疗方法。与主要的生物技术同类产品相比，该产品线被认为具有更高的临床风险，这反过来又具有可观的潜在价值。
Biogen与卫材在淀粉样蛋白阳性的早期阿尔茨海默氏病中对lecanemab的MAA的合作取得了进展，因为EMA的CHMP要求重新检查，尽管不包括 APOE4 纯合子，但还是提出了积极的建议。这一事态发展被认为使欧盟委员会更容易接受该申请，预计欧盟委员会将在67天的时间范围内就批准做出决定。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250

Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250

风险及免责提示

声明